Lexaria Bioscience

Lexaria Bioscience Earnings Yield

The Earnings Yield of Lexaria Bioscience (LEXX) as of Oct 15, 2026 is -76.82 %. In the previous year, Earnings Yield was -37.41 % — a change of 105.37% (lower).

Earnings Yield

-76.82 %

YoY

105.37%

Last updated:

Earnings Yield of Lexaria Bioscience is 2025 -76.82 % . Earnings Yield of Lexaria Bioscience was 2024 -37.41 % . It decreases by 105.37% lower compared to the previous year.

The Lexaria Bioscience Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2018
-42.59 USD
Jan 1, 2019
-26.46 USD
Jan 1, 2020
-25.39 USD
Jan 1, 2021
-25.99 USD
Jan 1, 2022
-46.92 USD
Jan 1, 2023
-43.02 USD
Jan 1, 2024
-37.41 USD
Jan 1, 2025
-76.82 USD
The Lexaria Bioscience Earnings Yield history
YEAREarnings YieldYoY
-76.82 %+105.37%
-37.41 %-13.05%
-43.02 %-8.31%
-46.92 %+80.51%
-25.99 %+2.36%
-25.39 %-4.04%
-26.46 %-37.88%
-42.59 %+253.02%
-12.07 %+53.88%
-7.84 %-31.39%
-11.43 %-5.38%
-12.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lexaria Bioscience Stock analysis

What does Lexaria Bioscience do? Lexaria Bioscience Corp, trading under the ticker LEXX, is a biotechnology company based in Kelowna, Canada, operating within the Health Care sector and Pharmaceuticals industry. The company, which went public via an IPO on October 28, 2009, currently employs five full-time staff members. Lexaria focuses on developing and commercializing its proprietary DehydraTECH drug delivery technology, designed to enhance the bioavailability of active pharmaceutical ingredients (APIs) when taken orally. The technology aims to improve how active molecules enter the bloodstream and has shown potential for enhanced delivery into brain tissue. Lexaria has also applied DehydraTECH to formulations for intraoral and topical administration, demonstrating improved bio-absorption in these delivery methods. The company operates through two business segments: Intellectual Property and Products. It maintains an in-house research laboratory and holds a portfolio of intellectual property, including 35 granted patents and numerous pending patents globally. Lexaria Bioscience Corp is headquartered in Kelowna, British Columbia, and its website is www.lexariabioscience.com. The company has no subsidiaries listed in the provided information, though a reference to a subsidiary named Lexa appears in the source description, which is treated as untrusted and thus excluded from this profile. Lexaria Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lexaria Bioscience stock

Earnings Yield of Lexaria Bioscience is -76.82 % in 2025.

Earnings Yield of Lexaria Bioscience changed from -37.41 % to -76.82 %, representing a 105.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield Lexaria Bioscience since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's Lexaria Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Lexaria Bioscience

All Key Metrics — Lexaria Bioscience